Estados Unidos · Plataformas y datos · MarketBeat

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Publicado por MarketBeat · Estados Unidos hace 50 min

Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

También te puede interesar

An OpenAI Model Spent Ethereum Without Permission. Here's What That Means For Crypto Investors.

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Ukraine says Starshield back to normal, Musk says Kyiv violated terms

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Booking vs. GameStop: Is Travel or Collectibles the Better Value Creator in Stocks?

Gene Munster Says Apple’s $2,200 iPhone Duo Could Add $8B To FY27 Revenue, Sees 20M Units In Sales Even As Wall Street Expects Only 12M

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Compartir

También te puede interesar

An OpenAI Model Spent Ethereum Without Permission. Here's What That Means For Crypto Investors.

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Ukraine says Starshield back to normal, Musk says Kyiv violated terms

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Booking vs. GameStop: Is Travel or Collectibles the Better Value Creator in Stocks?

Gene Munster Says Apple’s $2,200 iPhone Duo Could Add $8B To FY27 Revenue, Sees 20M Units In Sales Even As Wall Street Expects Only 12M